Vol. 23/No. 23

Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer.

With patents expiring on some of the revolutionary agents in cancer treatment, the emergence of biosimilars as a lower-cost option has seen exponential growth.

For patients with colon cancer, traditional clinical and pathologic risk factors may soon take a backseat as stratification tactics for determining optimal candidates for adjuvant chemotherapy.

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.

Ghassan K. Abou-Alfa, MD, discusses the administration of tremelimumab plus durvalumab in hepatocellular carcinoma and where the combination will fit in the treatment paradigm.

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.